Assay News and Research

RSS

How the cholesterol-lowering drug ezetimibe (Zetia) works

A new study in the June issue of Cell Metabolism, a Cell Press publication, sheds light on the action of the drug ezetimibe (trade name Zetia), which is used to treat high cholesterol. Ezetimibe is unique among cholesterol-lowering drugs in that it works by cutting the amount of cholesterol taken in from the diet rather than by blocking cholesterol's manufacture in the body.

3 Jun 2008

Anti-rejection drug sirolimus may prolong organ life in noncompliant kidney transplant patients

New research from the University of California, San Diego Department of Medicine, Division of Nephrology, shows that the anti-rejection drug sirolimus (brand name Rapamune) may help prolong the clinical benefit of transplanted kidneys and delay rejection, especially in patients who do not regularly take their prescribed medications (are "non-compliant"). While the transplant field has been highly successful at reducing rejection and graft loss in the first year, post-transplant, reducing risk for graft rejection in the long-term has proved more difficult.

2 Jun 2008

An alternative strategy for HIV vaccine research

Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.

22 May 2008

Study shows prostate cancer gene 3 (PCA3) correlates with severity of prostate cancer

A study published in the May 2008 issue of the peer-reviewed Journal of Urology demonstrates that the prostate cancer gene 3 (PCA3) can be used to detect and stratify stage and grade of prostate cancer.

8 May 2008

Blueberry juice beats other juices on antioxidant chart

USDA's database of antioxidant values for various foods, places blueberry juice at the top of the list among more than a dozen juices tested including pomegranate, apple, prune, cranberry and Concord grape

5 May 2008

Most comprehensive kinome collection

Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi's Sarcoma herpesvirus.

5 May 2008

New drug discovery tool for Alzheimer's disease

An article published in the April issue of the Journal of Alzheimer's Disease presents a detailed characterization of a new drug discovery tool for Alzheimer's disease.

28 Apr 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008

Discovery of fundamental mechanism of how tumour cells communicate

A new fundamental mechanism of how tumour cells communicate has just been discovered by the team of Dr. Janusz Rak at the Research Institute of the McGill University Health Centre (MUHC) in collaboration with Dr Guha from the University of Toronto.

21 Apr 2008

Distinguishing non-TB pulmonary disease from TB

A diagnostic kit shows new promise for distinguishing between tuberculosis (TB) and its infections from disease caused by related mycobacteria family, which mimic TB and other lung disease in symptoms but require distinctly different clinical treatments.

2 Apr 2008

New insights into anti-cancer effects of NSAIDs

Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis.

28 Mar 2008

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

New BARACLUDE (entecavir) data presented demonstrated a continued low incidence of resistance in nucleoside-naïve patients through five years of treatment. In the nucleoside-naïve chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108).

25 Mar 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

How is H pylori adhesion to gastric cells associated with MUC1 mucin VNTR size?

The Gram negative bacterium H pylori is involved in the pathogenesis of several gastrointestinal diseases, ultimately leading to gastric carcinoma.

19 Mar 2008

Cancer drug allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

14 Mar 2008

Simple laboratory test predicts risk of kidney injury after surgery

A simple laboratory test may provide a new way for doctors to identify patients at risk of developing potentially severe acute kidney injury (AKI) after surgery up to three days before the problem would otherwise be detected, reports a pilot study in the May 2008 issue of the Clinical Journal of the American Society of Nephrology .

14 Mar 2008

Simple laboratory test predicts risk of kidney injury after surgery

13 Mar 2008

Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells

Early detection of tumors is one of the Holy Grails of cancer research, an achievement that would greatly improve cancer therapy and prognosis. Two new reports describe different but promising approaches to solving this problem.

3 Mar 2008

IRIS International completes study of 85 post-prostatectomy patients using investigational NADiA PSA assay

IRIS International Inc. has announced that its Iris Molecular Diagnostics (IMD) group has successfully completed a retrospective study of stored leftover serum of 85 post-prostatectomy patients, men who had their prostate removed due to prostate cancer, using its investigational NADiA (Nucleic Acid Detection ImmunoAssay) PSA Assay.

27 Feb 2008

GeneSearch Breast Lymph Node Assay reduces recurrence of breast cancer

A new test that examines large sections of the sentinel lymph node for genes expressed by breast cancer could reduce the risk of recurrence and multiple surgeries, doctors say.

27 Feb 2008